retatrutide clinical trial obesity Another Promising Medication (Retatrutide) for TRIUMPH-3 🇦🇺 retatrutide cardiovascular/obesity clinical

In a recent RCT, ertugliflozin improved left ventricular global longitudinal strain in people with type 2 diabetes mellitus and pre-HF, effects associated with increased ACE2 and angiotensin (17) levels, suggesting a potential underlying mechanisms [91]

For semaglutide, it is 0.25 mg, then 0.5 mg, then 1 mg, then 1.7 mg, then 2.4 mg

The body composition benefits of the stack become clearly visible

Revenue per Patient

The beneficial role of tirzepatide on triglyceride levels could be at least partially explained by GIP-induced increased vascularization and lipid uptake in the adipose tissue [81]

Non-responders exist for both medications